Filing Flows

Filing Flows › Companies › Cryo Cell International › Cash flow

Cryo Cell International cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow$1.0M in Q3 FY26 · $4.7M over twelve months

Operating cash flow$1.1M
Capital spending−$102K
Free cash flow+$1.0M
Cash / net income0.9×
Cash conversion cycle-45 days

Analysis

In Q3 FY26, Cryo Cell International generated $1.1M of operating cash flow and spent $102K on capital projects, leaving free cash flow of $1.0M. That is $1.5M less than in Q3 FY25 ($2.5M).

Over the twelve months to Aug 31, 2026, operating cash flow was $4.9M; the largest uses were net borrowing (+) / repaid (−) ($3.4M), capital spending ($269K), other investing ($147K); besides operations, cash came from shares issued ($23K); the cash balance rose by $1.2M.

Operating cash flow was $1.1M against net income of $1.3M — 0.9× profit, less cash than reported earnings, worth checking against working capital. The largest differences: deferred revenue +$1.2M, prepaid and other assets −$671K, payables −$426K.

Its cash conversion cycle was -45 days (receivables 81 + inventory 24 − payables 150): suppliers fund its working capital.

Free cash flow

Cryo Cell International: free cash flow by quarterCryo Cell International: free cash flow by quarter$2.1MQ4 FY24$892KQ1 FY25$645KQ2 FY25$2.5MQ3 FY25$1.2MQ4 FY25$585KQ1 FY26$1.8MQ2 FY26$1.0MQ3 FY26
Operating cash flow less capital spending.
Cryo Cell International: operating cash flow against capital spendingCryo Cell International: operating cash flow against capital spendingOperating cash flowCapital spending$2.2M$8KQ4 FY24$954K$62KQ1 FY25$707K$62KQ2 FY25$2.5M$39KQ3 FY25$1.3M$67KQ4 FY25$652K$67KQ1 FY26$1.8M$33KQ2 FY26$1.1M$102KQ3 FY26
Latest (Q3 FY26): Operating cash flow $1.1M, Capital spending $102K.

Capital allocation, year by year

Cryo Cell International: where the cash came from (up) and went (down), by fiscal yearCryo Cell International: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksDividendsFY21: Operating cash flow $7.9MFY21: Net borrowing −$4.1MFY21: Shares issued $1.3MFY21: Capital spending −$1.8MFY21: Buybacks −$249K$9.2MFY21FY22: Operating cash flow $8.6MFY22: Net borrowing $9.3MFY22: Shares issued $551KFY22: Asset sales $1.9MFY22: Capital spending −$12.2MFY22: Buybacks −$1.8MFY22: Dividends −$7.7M$20.3MFY22FY23: Operating cash flow $8.9MFY23: Net borrowing −$1.2MFY23: Capital spending −$6.8MFY23: Buybacks −$799K$8.9MFY23FY24: Operating cash flow $6.0MFY24: Net borrowing $2.2MFY24: Shares issued $76KFY24: Capital spending −$2.4MFY24: Buybacks −$1.4MFY24: Dividends −$2.0M$8.2MFY24FY25: Operating cash flow $5.5MFY25: Net borrowing −$1.4MFY25: Shares issued $23KFY25: Asset sales $115KFY25: Capital spending −$230KFY25: Buybacks −$170KFY25: Dividends −$3.2M$5.6MFY25
Over these 5 years operating cash flow totalled $36.9M; the largest uses were capital spending ($23.5M) and dividends ($12.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4.2M
Debt$8.2M
Net debt$4.0M
Due within a year$184K

Cryo Cell International funds itself: free cash flow was $4.7M over the last twelve months, and $4.2M of cash and investments stands against $8.2M of debt ($184K due within a year, 23.0× covered by cash).

Cryo Cell International: debt maturities by year (FY25)Cryo Cell International: debt maturities by year (FY25)$184KYear 1$202KYear 2$214KYear 3$227KYear 4$242KYear 5$7.4MAfter year 5
Principal due in each year as disclosed in the annual report, against $4.2M of cash and investments now.

Where the cash came from and went

Cryo Cell International: sources (+) and uses (−) of cash, Q3 FY26Cryo Cell International: sources (+) and uses (−) of cash, Q3 FY26Operating cash flow$1.1MCash drawn (+) / kept (−)−$918KCapital spending−$102KOther investing−$79KNet borrowing (+) / repaid (−)−$43K
Cryo Cell International: sources (+) and uses (−) of cash, TTM to Q3 FY26Cryo Cell International: sources (+) and uses (−) of cash, TTM to Q3 FY26Operating cash flow$4.9MNet borrowing (+) / repaid (−)−$3.4MCash drawn (+) / kept (−)−$1.2MCapital spending−$269KOther investing−$147KShares issued$23K

From profit to cash

Cryo Cell International: net income to operating cash flow, Q3 FY26Cryo Cell International: net income to operating cash flow, Q3 FY26Net income$1.3MDepreciation & amortization$241KStock-based pay$93KReceivables−$313KInventory−$163KPayables−$426KAccrued liabilities−$402KDeferred revenue$1.2MPrepaid and other assets−$671KOperating cash flow$1.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 FY268124150-45
Q2 FY268118169-69
Q1 FY268021168-67
Q4 FY257928144-37
Q3 FY258134124-9
Q2 FY258235124-7
Q1 FY2582311059
Q4 FY24803910811

Every quarter

QuarterOperating cash flowCapital spendingBuybacksDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26$1.1M−$102K——−$43K—−$918K$1.0M
Q2 FY26$1.8M−$33K——−$1.6M—−$258K$1.8M
Q1 FY26$652K−$67K——−$740K—$69K$585K
Q4 FY25$1.3M−$67K——−$937K—−$54K$1.2M
Q3 FY25$2.5M−$39K−$81K—−$3.5M$23K−$128K$2.5M
Q2 FY25$707K−$62K−$89K−$1.2M$2.0M—$86K$645K
Q1 FY25$954K−$62K—−$2.0M$1.0M—$338K$892K
Q4 FY24$2.2M−$8K—−$2.0M$1.3M$75K−$364K$2.1M

Cryo Cell International: income statement and cash flow

Cryo Cell International, Q3 FY26: revenue $7.8M (0% year over year), operating margin 28.0%. The chart follows the revenue to costs, profit and cash.

Cryo Cell International: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.